Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates

Key Takeaways

• Recently released publications reveal evidence that rituximab leads to increased relapse rates relative to novel targeted therapies.
• The clinical significance of these findings emphasizes personalized treatment strategies, offering improved disease management and patient care.
• In practice, these data support the integration of novel therapies into standard protocols, aligning with observed improvements in patient outcomes.